Explore how cell‑free DNA z‑dbDNA™ offers a faster, more flexible alternative to plasmid DNA for making RNA vaccines and therapies.
Read More
Discover how Touchlight’s novel circular DNA architectures—mbDNA™, sscDNA, hsscDNA, and dscDNA—enable precise, efficient gene insertion for next‑generation gene editing and non‑viral gene therapy.
Read More
Unlock how dbDNA™ can reduce AAV gene therapy manufacturing costs and enhance efficiency.
Read More
MegaBulb DNA: Enabling better non-viral gene therapy with mbDNA – a cell-free circular ssDNA
Read More
Touchlight’s dbDNA™ enables fast, scalable GMP-grade AAV production with fewer impurities and no bacterial sequences, confirmed by nanopore sequencing.
Read More
Transient transfection remains the most widely used method for AAV manufacturing, but it can be difficult to optimize due to competing process requirements. Factors such as cell density, DNA concentration,…
Read More
Recent advancements in non-viral gene editing technologies offer precise genome engineering at significantly reduced costs and biosafety risks compared to viruses. CRISPR is a programmable genome targeting system, which relies…
Read More
Here, we demonstrate that dbDNATM can be optimised for the manufacture of high titre LVV.
Read More
A critical bottleneck for rapid onset of clinical trials as well as for resilient supply of commercial RNA products is the production of plasmid DNA, which is routinely used as…
Read More
Download the poster here
Read More
